214 related articles for article (PubMed ID: 10233261)
1. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
[TBL] [Abstract][Full Text] [Related]
2. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate.
Dréno B; Claudy A; Meynadier J; Verret JL; Souteyrand P; Ortonne JP; Kalis B; Godefroy WY; Beerblock K; Thill L
Br J Dermatol; 1991 Nov; 125(5):456-9. PubMed ID: 1751352
[TBL] [Abstract][Full Text] [Related]
3. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
4. Interferon alpha-2a in cutaneous T-cell lymphoma.
Vegna ML; Papa G; Defazio D; Pisani F; Coppola G; De Pità O; Puddu P; Ferranti G; Simoni R; Mandelli F
Eur J Haematol Suppl; 1990; 52():32-5. PubMed ID: 2279544
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
[TBL] [Abstract][Full Text] [Related]
6. Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.
Anadolu RY; Birol A; Sanli H; Erdem C; Türsen U
Int J Dermatol; 2005 Jul; 44(7):559-65. PubMed ID: 15985024
[TBL] [Abstract][Full Text] [Related]
7. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
[TBL] [Abstract][Full Text] [Related]
9. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
[TBL] [Abstract][Full Text] [Related]
11. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
Querfeld C; Rosen ST; Kuzel TM; Kirby KA; Roenigk HH; Prinz BM; Guitart J
Arch Dermatol; 2005 Mar; 141(3):305-11. PubMed ID: 15781671
[TBL] [Abstract][Full Text] [Related]
13. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.
Simoni R; Cavalieri R; Coppola G; Ricciotti L; De Pità O; Criscuolo D; Covelli A; Papa G; Mandelli F
J Biol Regul Homeost Agents; 1987; 1(2):93-9. PubMed ID: 3504088
[TBL] [Abstract][Full Text] [Related]
14. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
15. Combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Lemak NA; Redman JR; Eifel PJ; Tucker SL; Cabanillas FF; Kurzrock R
J Am Acad Dermatol; 1996 Jun; 34(6):1022-9. PubMed ID: 8647968
[TBL] [Abstract][Full Text] [Related]
16. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.
Chiarion-Sileni V; Bononi A; Fornasa CV; Soraru M; Alaibac M; Ferrazzi E; Redelotti R; Peserico A; Monfardini S; Salvagno L
Cancer; 2002 Aug; 95(3):569-75. PubMed ID: 12209749
[TBL] [Abstract][Full Text] [Related]
18. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
[TBL] [Abstract][Full Text] [Related]
19. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
20. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.
Hughes CF; Khot A; McCormack C; Lade S; Westerman DA; Twigger R; Buelens O; Newland K; Tam C; Dickinson M; Ryan G; Ritchie D; Wood C; Prince HM
Blood; 2015 Jan; 125(1):71-81. PubMed ID: 25336628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]